Delsol
08.03.2007, 18:42
Хочу сообщить коллегам о новой публикации (Review) в Endocrinolоgy and Metabolism Clinic
Endocrinol Metab Clin North Am. 2006 Dec;35(4):687-98,
Myxedema coma.
Wartofsky L.
Department of Medicine, Washington Hospital Center, Washington, DC 20010-2975, USA. [Ссылки могут видеть только зарегистрированные и активированные пользователи]
Myxedema coma is the term given to the most severe presentation of profound hypothyroidism and is often fatal in spite of therapy. Decompensation of the hypothyroid patient into a coma may be precipitated by a number of drugs, systemic illnesses (eg, pneumonia), and other causes. It typically presents in older women in the winter months and is associated with signs of hypothyroidism, hypothermia, hyponatremia, hypercarbia, and hypoxemia. Treatment must be initiated promptly in an intensive care unit setting. Although thyroid hormone therapy is critical to survival, it remains uncertain whether it should be administered as thyroxine, triiodothyronine, or both. Adjunctive measures, such as ventilation, warming, fluids, antibiotics, pressors, and corticosteroids, may be essential for survival.
Еще одна интересная публикация появилась в журнале Diabetes Care:
Diabetes Care 30:471-478, 2007
Effects of Medical Therapy on Insulin Resistance and the Cardiovascular System in Polycystic Ovary Syndrome
Caroline Meyer, PHD1, Barry P. McGrath, MD1 and Helena Jane Teede, PHD1,2
1 Centre for Vascular Health, Department of Medicine, Monash University, Melbourne, Victoria, Australia
2 Jean Hailes Foundation for Women’s Health, Monash Institute for Health Services Research, Southern Health, Melbourne, Victoria, Australia
CONCLUSIONS—In overweight women with PCOS, metformin and low- and high-dose OCP preparations have similar efficacy but differential effects on insulin resistance and arterial function. These findings suggest that a low-dose OCP preparation may be preferable if contraception is needed and that metformin should be considered for symptomatic management, particularly in women with additional metabolic and cardiovascular risk factors.
[Ссылки могут видеть только зарегистрированные и активированные пользователи]
Endocrinol Metab Clin North Am. 2006 Dec;35(4):687-98,
Myxedema coma.
Wartofsky L.
Department of Medicine, Washington Hospital Center, Washington, DC 20010-2975, USA. [Ссылки могут видеть только зарегистрированные и активированные пользователи]
Myxedema coma is the term given to the most severe presentation of profound hypothyroidism and is often fatal in spite of therapy. Decompensation of the hypothyroid patient into a coma may be precipitated by a number of drugs, systemic illnesses (eg, pneumonia), and other causes. It typically presents in older women in the winter months and is associated with signs of hypothyroidism, hypothermia, hyponatremia, hypercarbia, and hypoxemia. Treatment must be initiated promptly in an intensive care unit setting. Although thyroid hormone therapy is critical to survival, it remains uncertain whether it should be administered as thyroxine, triiodothyronine, or both. Adjunctive measures, such as ventilation, warming, fluids, antibiotics, pressors, and corticosteroids, may be essential for survival.
Еще одна интересная публикация появилась в журнале Diabetes Care:
Diabetes Care 30:471-478, 2007
Effects of Medical Therapy on Insulin Resistance and the Cardiovascular System in Polycystic Ovary Syndrome
Caroline Meyer, PHD1, Barry P. McGrath, MD1 and Helena Jane Teede, PHD1,2
1 Centre for Vascular Health, Department of Medicine, Monash University, Melbourne, Victoria, Australia
2 Jean Hailes Foundation for Women’s Health, Monash Institute for Health Services Research, Southern Health, Melbourne, Victoria, Australia
CONCLUSIONS—In overweight women with PCOS, metformin and low- and high-dose OCP preparations have similar efficacy but differential effects on insulin resistance and arterial function. These findings suggest that a low-dose OCP preparation may be preferable if contraception is needed and that metformin should be considered for symptomatic management, particularly in women with additional metabolic and cardiovascular risk factors.
[Ссылки могут видеть только зарегистрированные и активированные пользователи]